Effectiveness of alteplase in the very elderly after acute ischemic stroke

Josef Yayan Department of Internal Medicine, University Hospital of Saarland, Homburg/Saar, Germany Abstract: Alteplase has traditionally been the only pharmacologic agent available for treating acute ischemic stroke worldwide, and is considered an effective and safe therapeutic drug for acute cere...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yayan J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	tissue-plasminogen activator old age safety tolerability intracerebral hemorrhage Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/b4c0cf703c054f7687c38edaed22e819
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4c0cf703c054f7687c38edaed22e819
record_format	dspace
spelling	oai:doaj.org-article:b4c0cf703c054f7687c38edaed22e8192021-12-02T00:12:00ZEffectiveness of alteplase in the very elderly after acute ischemic stroke1178-1998https://doaj.org/article/b4c0cf703c054f7687c38edaed22e8192013-07-01T00:00:00Zhttps://www.dovepress.com/effectiveness-of-alteplase-in-the-very-elderly-after-acute-ischemic-st-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Josef Yayan Department of Internal Medicine, University Hospital of Saarland, Homburg/Saar, Germany Abstract: Alteplase has traditionally been the only pharmacologic agent available for treating acute ischemic stroke worldwide, and is considered an effective and safe therapeutic drug for acute cerebral ischemia. However, the drug is usually indicated for use in patients aged <81 years due to insufficient literature regarding the drug's safety in older individuals. Nevertheless, the elderly can benefit from alteplase after they experience an acute ischemic stroke. Age differences have been observed in the clinical presentation of acute ischemic stroke; however, the safety and efficacy of alteplase for patients with acute ischemic stroke do not depend on age or sex. Evidence of an increasing rate of intracerebral hemorrhage among the elderly with acute ischemic stroke, following alteplase treatment, has not been reported. Severe intracranial hemorrhage is a known side effect of alteplase but is not associated with age in patients with acute ischemic stroke. Alteplase can be used safely and effectively to treat elderly patients who suffer an acute ischemic stroke, including those over the age of 80 years. Keywords: tissue-plasminogen activator, old age, safety, tolerability, intracerebral hemorrhageYayan JDove Medical Pressarticletissue-plasminogen activatorold agesafetytolerabilityintracerebral hemorrhageGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 963-974 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	tissue-plasminogen activator old age safety tolerability intracerebral hemorrhage Geriatrics RC952-954.6
spellingShingle	tissue-plasminogen activator old age safety tolerability intracerebral hemorrhage Geriatrics RC952-954.6 Yayan J Effectiveness of alteplase in the very elderly after acute ischemic stroke
description	Josef Yayan Department of Internal Medicine, University Hospital of Saarland, Homburg/Saar, Germany Abstract: Alteplase has traditionally been the only pharmacologic agent available for treating acute ischemic stroke worldwide, and is considered an effective and safe therapeutic drug for acute cerebral ischemia. However, the drug is usually indicated for use in patients aged <81 years due to insufficient literature regarding the drug's safety in older individuals. Nevertheless, the elderly can benefit from alteplase after they experience an acute ischemic stroke. Age differences have been observed in the clinical presentation of acute ischemic stroke; however, the safety and efficacy of alteplase for patients with acute ischemic stroke do not depend on age or sex. Evidence of an increasing rate of intracerebral hemorrhage among the elderly with acute ischemic stroke, following alteplase treatment, has not been reported. Severe intracranial hemorrhage is a known side effect of alteplase but is not associated with age in patients with acute ischemic stroke. Alteplase can be used safely and effectively to treat elderly patients who suffer an acute ischemic stroke, including those over the age of 80 years. Keywords: tissue-plasminogen activator, old age, safety, tolerability, intracerebral hemorrhage
format	article
author	Yayan J
author_facet	Yayan J
author_sort	Yayan J
title	Effectiveness of alteplase in the very elderly after acute ischemic stroke
title_short	Effectiveness of alteplase in the very elderly after acute ischemic stroke
title_full	Effectiveness of alteplase in the very elderly after acute ischemic stroke
title_fullStr	Effectiveness of alteplase in the very elderly after acute ischemic stroke
title_full_unstemmed	Effectiveness of alteplase in the very elderly after acute ischemic stroke
title_sort	effectiveness of alteplase in the very elderly after acute ischemic stroke
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/b4c0cf703c054f7687c38edaed22e819
work_keys_str_mv	AT yayanj effectivenessofalteplaseintheveryelderlyafteracuteischemicstroke
_version_	1718403884498550784

Effectiveness of alteplase in the very elderly after acute ischemic stroke

Ejemplares similares